Drugs / ABC/DTG/3TC
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT02607930 Comparator | Nov 2015 → May 2017 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABC/DTG/3TC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02607930 ↗ |
| Route | Oral | “600/50/300 milligrams (mg) tablets administered orally” NCT02607930 ↗ |